Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata
Open accessAbstract
Loss of nigrostriatal dopaminergic neurons in Parkinson's disease (PD) leads to increased activity of glutamatergic neurons in the subthalamic nucleus (STN). Recent studies reveal that the resultant increase in STN-induced excitation of basal ganglia output nuclei is responsible for the disabling motor impairment characteristic of PD. On the basis of this, it is possible that any manipulation that reduces activity at excitatory STN synapses onto basal ganglia output nuclei could be useful in the treatment of PD. We now report that group II metabotropic glutamate receptors (mGluRs) are presynaptically localized on STN terminals and that activation of these receptors inhibits excitatory transmission at STN synapses. In agreement with the hypothesis that this could provide a therapeutic benefit in PD, a selective agonist of group II mGluRs induces a dramatic reversal of catalepsy in a rat model of PD. These results raise the exciting possibility that selective agonists of group II mGluRs could provide an entirely new approach to the treatment of PD. These novel therapeutic agents would provide a noninvasive pharmacological treatment that does not involve the manipulation of dopaminergic systems, thus avoiding the problems associated with current therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of mGluR2s can inhibit GABA release through a presynaptic mechanism.
“It was shown that activation of mGluR2s can also regulate release of other neurotransmitters: it can inhibit GABA release via a presynaptic mechanism (Bradley et al. 2000; Pilc et al. 2008).”
From Short- and Long-Term Consequences of Nicotine Exposure during Adolescence for Prefrontal Cortex Neuronal Network Function (2012) · cites this paper as Bradley et al. 2000
In the section on the presynaptic mechanism (page unavailable), the paper says group II mGluRs likely inhibit glutamate release from presynaptic terminals, not GABA release. Its reference to GABAergic neurons identifies the cells receiving that excitatory input; it does not identify the transmitter being released by the affected terminals. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation
Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Bas, J. L., Perret, J., Benabid, A., & Broussolle, E. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90062-4 · Cited by 1,480 · see citing works
Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.
Laitinen, L., Bergenheim, A. T., & Hariz, M. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.1.0053 · Cited by 1,120 · see citing works
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116 · see citing works
Kita, H., & Kitai, S. T. (1987) · The Journal of Comparative Neurology · doi:10.1002/cne.902600309 · Cited by 591 · see citing works
Alternative excitotoxic hypotheses
Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574 · cited 1× · see citing works
“Furthermore, glutamate has been implicated as an excitotoxic agent in PD (Albin and Greenamyre, 1992; Rodriguez et al., 1998), suggesting that increased excitatory drive to the SNc may contribute to the progressive loss of SNc dopaminergic neurons in PD.”
BackgroundBaron, M. S., Vitek, J. L., Green, J., Kaneoke, Y., Hashimoto, T., Turner, R. S., Woodard, J. L., DeLong, M. R., Bakay, R. A. E., Cole, S. A., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400305 · Cited by 559 · see citing works
Ohishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · The Journal of Comparative Neurology · doi:10.1002/cne.903350209 · Cited by 514 · see citing works
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
Testa, C. M., Standaert, D. G., Young, A. R., & Penney, J. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-05-03005.1994 · Cited by 511 · see citing works
Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection
Rodríguez‐Oroz, M., Obeso, J. A., & Olanow, C. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440726 · Cited by 399 · see citing works
Luján, R., Roberts, J. D. B., Shigemoto, R., Ohishi, H., & Somogyi, P. (1997) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(97)00051-3 · Cited by 395 · see citing works
Monn, J. A., Valli, M. J., Massey, S. M., Wright, R. A., Salhoff, C. R., Johnson, B. G., Howe, T. J., Alt, C. A., Rhodes, G. A., Robey, R. L., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606756 · Cited by 390 · see citing works
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
Kingston, A., Ornstein, P. L., Wright, R. A., Johnson, B. G., Mayne, N. G., Burnett, J. P., Belagaje, R. M., Wu, S., & Schoepp, D. D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(97)00191-3 · Cited by 369 · see citing works
Gereau, R., & Conn, P. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06879.1995 · Cited by 352 · see citing works
Self-citationRole of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb
Hayashi, Y., Momiyama, A., Takahashi, T., Ohishi, H., Ogawa-Meguro, R., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1993) · Nature · doi:10.1038/366687a0 · Cited by 350 · see citing works
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Kornhuber, J., Weller, M., Schoppmeyer, K., & Riederer, P. (1994) · PubMed · Cited by 290 · see citing works
Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279 · see citing works
Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., & Conn, P. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11465 · Cited by 275 · see citing works
Self-citationTesta, C. M., Friberg, I. K., Weiss, S. W., & Standaert, D. G. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980105)390:1 · Cited by 237 · see citing works
Lovinger, D. M., & McCool, B. A. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.73.3.1076 · Cited by 235 · see citing works
Richards, C. D., Shiroyama, T., & Kitai, S. T. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00093-6 · Cited by 233 · see citing works
Schoepp, D. D., Johnson, B. G., Wright, R. A., Salhoff, C. R., Mayne, N. G., Wu, S., Cockerham, S. L., Burnett, J. P., BELEGAJE, R., Bleakman, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225 · see citing works
Vercueil, L., Benazzouz, A., Deransart, C., Bressand, K., Marescaux, C., Depaulis, A., & Benabid, A. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00011-4 · Cited by 212 · see citing works
Bradley, S., Levey, A. I., Hersch, S. M., & Conn, P. J. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02044.1996 · Cited by 209 · see citing works
Self-citationNeki, A., Ohishi, H., Kaneko, T., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12248-6 · Cited by 186 · see citing works
The role of basal ganglia in the control of generalized absence seizures
Deransart, C., Vercueil, L., Marescaux, C., & Depaulis, A. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00053-9 · Cited by 175 · see citing works
Dopamine D1Receptors Facilitate GABAASynaptic Currents in the Rat Substantia Nigra Pars Reticulata
Radnikow, G., & Misgeld, U. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02009.1998 · Cited by 171 · see citing works
Low‐dose L‐dopa therapy in Parkinson's disease
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163 · see citing works
Gereau, R. W., & Conn, P. J. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.74.1.122 · Cited by 161 · see citing works
Self-citationParfitt, K. D., & Madison, D. V. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019900 · Cited by 160 · see citing works
GPi pallidotomy for dystonia: clinical outcome and neuronal activity.
Vitek, J. L., Zhang, J., Evatt, M. L., Mewes, K., DeLong, M. R., Hashimoto, T., Triche, S. D., & Bakay, R. A. E. (1998) · PubMed · Cited by 142 · see citing works
Scanziani, M., Gähwiler, B. H., & Thompson, S. M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00119-q · Cited by 141 · see citing works
Models of Basal Ganglia Function and Pathophysiology of Movement Disorders
Wichmann, T., & DeLong, M. R. (1998) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(18)30261-4 · Cited by 129 · see citing works
Doze, V. A., Cohen, G. A., & Madison, D. V. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.74.1.43 · Cited by 125 · see citing works
Iribe, Y., Moore, K., Pang, K. C. H., & Tepper, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.2.925 · Cited by 117 · see citing works
Pisani, A., Calabresi, P., Centonze, D., & Bernardi, G. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00177-3 · Cited by 106 · see citing works
Ultrastructure and synaptic targets of the raphe-nigral projection in the rat
Corvaja, N., Doucet, G., & Bolam, J. P. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90510-m · Cited by 101 · see citing works
Konieczny, J., Ossowska, K., Wolfarth, S., & Pilc, A. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005284 · Cited by 96 · see citing works
Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy
Ossowska, K., Karcz, M., Wardas, J., & Wolfarth, S. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90291-d · Cited by 95 · see citing works
Pharmacological treatment of Parkinson’s disease
Münchau, A. M., & Bhatia, K. P. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.900.602 · Cited by 93 · see citing works
Sacaan, A. I., Monn, J., & Schoepp, D. D. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20329-9 · Cited by 85 · see citing works
Deransart, C., Marescaux, C., & Depaulis, A. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00471-8 · Cited by 84 · see citing works
Bevan, M. D., Bolam, J. P., & Crossman, A. R. (1994) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1994.tb00275.x · Cited by 82 · see citing works
Toms, N. J., Jane, D. E., Kemp, M. C., Bedingfield, J. S., & Roberts, P. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15750.x · Cited by 77 · see citing works
Schoepp, D. D., Johnson, B. G., Salhoff, C. R., Valu, M. J., Desai, M. A., Burnett, J. P., Mayne, N. G., & Monn, J. A. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00061-a · Cited by 74 · see citing works
Wigmore, M. A., & Lacey, M. G. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701662 · Cited by 73 · see citing works
Starr, M. S. (1995) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251229 · Cited by 69 · see citing works
Guridi, J., & Obeso, J. A. (1997) · PubMed · Cited by 66 · see citing works
Kaatz, K. W., & Albin, R. L. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00568-p · Cited by 65 · see citing works
The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist
Klockgether, T., Jacobsen, P., Löschmann, P. A., & Turski, L. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251200 · Cited by 53 · see citing works
Deransart, C., Riban, V., Pham-Lê, B.-T., Hechler, V., Marescaux, C., & Depaulis, A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00113-5 · Cited by 41 · see citing works
Schmidt, W., Schuster, G., Wacker, E., & Pergande, G. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)89671-9 · Cited by 30 · see citing works
Schaffhauser, H., Cartmell, J., Jakob-Røtne, R., & Mutel, V. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00079-8 · Cited by 30 · see citing works
Kronthaler, U. O., & Schmidt, W. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00673-5 · Cited by 19 · see citing works
Zahm (1996) · doi:10.1002/(sici)1096-9861(19960108)364:2
Flagged first, then by citations
Research works printed but not linked: 1
- Wichmann T, DeLong MR (1997) Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. In: Movement disorders: neurological principles and practice (Watts RL, ed), pp 87-97. New York: McGraw-Hill.
Cited by
Sorted by citations
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063 · see citing works
Awad, H., Hubert, G. W., Smith, Y., Levey, A. I., & Conn, P. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-21-07871.2000 · Cited by 423 · see citing works
Self-citationMetabotropic glutamate receptors in the basal ganglia motor circuit
Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1763 · Cited by 330 · see citing works
Self-citationGoriounova, N. A., & Mansvelder, H. D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012120 · Cited by 307 · see citing works
“It was shown that activation of mGluR2s can also regulate release of other neurotransmitters: it can inhibit GABA release via a presynaptic mechanism (Bradley et al. 2000; Pilc et al. 2008).”
BackgroundGlutamate Receptors as Therapeutic Targets for Parkinsons Disease
Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824606 · Cited by 251 · see citing works
Self-citationMarino, M. J., Williams, D. L., O’Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835724100 · Cited by 240 · see citing works
Self-citationDevelopment of allosteric modulators of GPCRs for treatment of CNS disorders
Nickols, H. H., & Conn, P. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 227 · see citing works
Self-citationLY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. L., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207 · see citing works
The pars reticulata of the substantia nigra: a window to basal ganglia output
Deniau, J., Mailly, P., Maurice, N., & Charpier, S. (2007) · Progress in brain research · doi:10.1016/s0079-6123(06)60009-5 · Cited by 186 · see citing works
Spooren, W. P. J. M., Ballard, T. M., Gasparini, F., Amalric, M., Mutel, V., & Schreiber, R. (2003) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000081783.35927.8f · Cited by 177 · see citing works
Gubellini, P., Pisani, A., Centonze, D., Bernardi, G., & Calabresi, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.005 · Cited by 165 · see citing works
Movement of ‘gating charge’ is coupled to ligand binding in a G-protein-coupled receptor
Ben-Chaim, Y., Chanda, B., Dascal, N., Bezanilla, F., Parnas, I., & Parnas, H. (2006) · Nature · doi:10.1038/nature05259 · Cited by 164 · see citing works
Rouse, S. T., Marino, M. J., Bradley, S. R., Awad, H., Wittmann, M., & Conn, P. J. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00098-x · Cited by 162 · see citing works
Self-citationBook Review: Metabotropic Glutamate Receptors: Electrical and Chemical Signaling Properties
Coutinho, V., & Knöpfel, T. (2002) · The Neuroscientist · doi:10.1177/1073858402238514 · Cited by 144 · see citing works
Enantioselective Oxidative Gold Catalysis Enabled by a Designed Chiral P,N‐Bidentate Ligand
Ji, K., Zheng, Z., Wang, Z., & Zhang, L. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201409300 · Cited by 134 · see citing works
Regulation of neuronal communication by G protein‐coupled receptors
Huang, Y., & Thathiah, A. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.007 · Cited by 131 · see citing works
Marino, M. J., Wittmann, M., Bradley, S. R., Hubert, G. W., Smith, Y., & Conn, P. J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07001.2001 · Cited by 122 · see citing works
Self-citationMetabotropic Glutamate Receptors as Targets for Multipotential Treatment of Neurological Disorders
Byrnes, K. R., Loane, D. J., & Faden, A. I. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.038 · Cited by 119 · see citing works
Ossowska, K., Konieczny, J., Wolfarth, S., Wierońska, J. M., & Pilc, A. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00083-1 · Cited by 116 · see citing works
Galván, A., Kuwajima, M., & Smith, Y. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.019 · Cited by 109 · see citing works
Selective involvement of mGlu1 receptors in corticostriatal LTD
Gubellini, P., Saulle, E., Centonze, D., Bonsi, P., Pisani, A., Bernardi, G., Conquet, F., & Calabresi, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00021-1 · Cited by 107 · see citing works
Linden, A.-M., Greene, S. J., Bergeron, M., & Schoepp, D. D. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300321 · Cited by 106 · see citing works
Ritzén, A., Mathiesen, J. M., & Thomsen, C. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_156.x · Cited by 104 · see citing works
Corticostriatal LTP requires combined mGluR1 and mGluR5 activation
Gubellini, P., Saulle, E., Centonze, D., Costa, C., Tropepi, D., Bernardi, G., Conquet, F., & Calabresi, P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00214-9 · Cited by 97 · see citing works
Glutamate Receptors and Parkinson???s Disease
Marino, M. J., Valenti, O., & Conn, P. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320050-00006 · Cited by 97 · see citing works
Self-citationBustos, G. A., Abarca, J., Campusano, J. M., Bustos, V., Noriega, V., & Aliaga, E. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.05.002 · Cited by 96 · see citing works
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 93 · see citing works
Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease
Dalfó, E., Barrachina, M., Rosa, J. L., Ambrosio, S., & Ferrer, I. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.001 · Cited by 94 · see citing works
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
Murray, T. K., Messenger, M. J., Ward, M., Woodhouse, S., Osborne, D. J., Duty, S., & O’Neill, M. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00842-0 · Cited by 93 · see citing works
Wittmann, M., Marino, M. J., Bradley, S. R., & Conn, P. J. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.5.1960 · Cited by 87 · see citing works
Self-citationAsymmetric Sulfonium Ylide Mediated Cyclopropanation: Stereocontrolled Synthesis of (+)‐LY354740
Aggarwal, V. K., & Grange, E. (2005) · Chemistry - A European Journal · doi:10.1002/chem.200500693 · Cited by 86 · see citing works
Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus
Poisik, O. V., Mannaioni, G., Traynelis, S. F., Smith, Y., & Conn, P. J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00122.2003 · Cited by 86 · see citing works
Self-citationMessenger, M. J., Dawson, L., & Duty, S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00090-4 · Cited by 80 · see citing works
Therapeutic promise and principles: Metabotropic glutamate receptors
Maiese, K., Chong, Z. Z., Shang, Y., & Hou, J.-L. (2008) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.1.1.6842 · Cited by 58 · see citing works
The Metabotropic Glutamate G-protein-coupled Receptors mGluR3 and mGluR1a Are Voltage-sensitive
Ohana, L., Barchad, O., Parnas, I., & Parnas, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513447200 · Cited by 74 · see citing works
Adedoyin, M. O., Vicini, S., & Neale, J. H. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-60 · Cited by 73 · see citing works
Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia
Smith, Y., Charara, A., Paquet, M., Kieval, J. Z., Paré, J., Hanson, J. E., Hubert, G. W., Kuwajima, M., & Levey, A. I. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00098-9 · Cited by 72 · see citing works
Self-citationVernon, A. C., Palmer, S., Datla, K. P., Zbarsky, V., Croucher, M. J., & Dexter, D. T. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04362.x · Cited by 71 · see citing works
Battaglia, G., Busceti, C. L., Pontarelli, F., Biagioni, F., Fornai, F., Paparelli, A., Bruno, V., Ruggieri, S. A., & Nicoletti, F. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00146-1 · Cited by 70 · see citing works
Matsui, T., & Kita, H. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.032 · Cited by 70 · see citing works
Dalfó, E., Albasanz, J. L., Martı́n, M., & Ferrer, I. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00082.x · Cited by 68 · see citing works
Waku, I., Magalhães, M. S., Alves, C. D. O., & de Oliveira, A. R. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15222 · Cited by 67 · see citing works
Goriounova, N. A., & Mansvelder, H. D. (2012) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2012.00003 · Cited by 65 · see citing works
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Gasparini, F., Paolo, T. D., & Gomez‐Mancilla, B. (2013) · Parkinson s Disease · doi:10.1155/2013/196028 · Cited by 63 · see citing works
Ossowska, K., Konieczny, J., Wardas, J., Pietraszek, M., Kuter, K. Z., Wolfarth, S., & Pilc, A. (2006) · Amino Acids · doi:10.1007/s00726-006-0317-y · Cited by 61 · see citing works
Muly, E. C., Mania, I., Guo, J., & Rainnie, D. G. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21525 · Cited by 59 · see citing works
MacInnes, N., Messenger, M. J., & Duty, S. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705566 · Cited by 56 · see citing works
Zhang, Y., Liu, Y., Kang, X.-P., Dou, C.-Y., Zhuo, R., Huang, S., Peng, L., & Wen, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.012 · Cited by 56 · see citing works
Samadi, P., Grégoire, L., Morissette, M., Calon, F., Tahar, A. H., Bélanger, N., Dridi, M., Bédard, P. J., & Paolo, T. D. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.009 · Cited by 56 · see citing works
Maiese, K., Chong, Z. Z., & Li, F. (2005) · Current Neurovascular Research · doi:10.2174/156720205774962692 · Cited by 56 · see citing works
Ammari, R., Lopez, C., Bioulac, B. H., García, L., & Hammond, C. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.011 · Cited by 55 · see citing works
Richards, G. J., Messer, J., Malherbe, P., Pink, R., Brockhaus, M., Stadler, H., Wichmann, J., Schaffhauser, H., & Mutel, V. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20538 · Cited by 53 · see citing works
Poisik, O. V., Raju, D. V., Verreault, M., Rodriguez, A. L., Abeniyi, O. A., Conn, P. J., & Smith, Y. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.006 · Cited by 53 · see citing works
Self-citationSubthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro
Shen, K., & Johnson, S. W. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.110031 · Cited by 52 · see citing works
Metabotropic glutamate 2/3 receptors as drug targets
Marek, G. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.003 · Cited by 52 · see citing works
Galván, A., Hu, X., Rommelfanger, K. S., Paré, J., Khan, Z. U., Smith, Y., & Wichmann, T. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00849.2013 · Cited by 49 · see citing works
Metabotropic Glutamate Receptors in Central Nervous System Diseases
Golubeva, A. V., Moloney, R. D., O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150316224011 · Cited by 49 · see citing works
Cobb, W. S., & Abercrombie, E. D. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-04-01407.2002 · Cited by 47 · see citing works
Incontro, S., Musella, M. L., Sammari, M., Scala, C. D., Fantini, J., & Debanne, D. (2024) · Physiological Reviews · doi:10.1152/physrev.00004.2024 · Cited by 48 · see citing works
Lovelace, J. W., Corches, A., Vieira, P. A., Hiroto, A. S., Mackie, K., & Korzus, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.034 · Cited by 43 · see citing works
Wittmann, M., Marino, M. J., & Conn, P. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033266 · Cited by 41 · see citing works
Self-citationMarino, M. J., Awad, H., Ciombor, K. J., & Conn, P. J. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00097-7 · Cited by 40 · see citing works
Self-citationInvestigational drugs under development for the treatment of PTSD
Ragen, B., Seidel, J., Chollak, C., Pietrzak, R. H., & Neumeister, A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1020109 · Cited by 37 · see citing works
Marino, M. J., Awad, H., Poisik, O. V., Wittmann, M., & Conn, P. J. (2002) · Amino Acids · doi:10.1007/s00726-001-0127-1 · Cited by 37 · see citing works
Self-citationAwad, H., & Conn, P. J. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00047-8 · Cited by 37 · see citing works
Self-citationGautam, D., Naik, U. P., Naik, M. U., Yadav, S. K., Chaurasia, R. N., & Dash, D. (2023) · Biomolecules · doi:10.3390/biom13111609 · Cited by 37 · see citing works
Enantioselective Oxidative Gold Catalysis Enabled by a Designed Chiral P,N‐Bidentate Ligand
Ji, K., Zheng, Z., Wang, Z., & Zhang, L. (2014) · Angewandte Chemie · doi:10.1002/ange.201409300 · Cited by 36 · see citing works
Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients
Samadi, P., Rajput, A. H., Calon, F., Grégoire, L., Hornykiewicz, O., Rajput, A. H., & Paolo, T. D. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819cabe4 · Cited by 36 · see citing works
Parnas, H., & Parnas, I. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.12.001 · Cited by 35 · see citing works
Grassi, S., Frondaroli, A., & Pettorossi, V. E. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.023424 · Cited by 34 · see citing works
Radioligands for the PET Imaging of Metabotropic Glutamate Receptor Subtype 5 (mGluR5)
Mu, L., Schubiger, P. A., & Ametamey, S. M. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610793176783 · Cited by 33 · see citing works
Chan, H. H. N., Paur, H., Vernon, A. C., Zabarsky, V., Datla, K. P., Croucher, M. J., & Dexter, D. T. (2010) · Parkinson s Disease · doi:10.4061/2010/190450 · Cited by 33 · see citing works
Katayama, J., Akaike, N., & Nabekura, J. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00202-x · Cited by 33 · see citing works
Polo-Like Kinase 2: From Principle to Practice
Zhang, C., Ni, C., & Lu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956225 · Cited by 32 · see citing works
Johnson, K. A., Niswender, C. M., Conn, P. J., & Xiang, Z. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.09.007 · Cited by 31 · see citing works
Self-citationOssowska, K., Pietraszek, M., Wardas, J., & Wolfarth, S. (2004) · PubMed · Cited by 31 · see citing works
Fukuyama, K., Fukuzawa, M., Shiroyama, T., & Okada, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110070 · Cited by 28 · see citing works
Chen, L., Liu, Z., Zeng-min, T., Wang, Y., & Li, S. (2000) · Stereotactic and Functional Neurosurgery · doi:10.1159/000048385 · Cited by 28 · see citing works
The role of striatal metabotropic glutamate receptors in Parkinson's disease
Ossowska, K., Konieczny, J., Wardas, J., Gołembiowska, K., Wolfarth, S., & Pilc, A. (2002) · Amino Acids · doi:10.1007/s00726-001-0128-0 · Cited by 27 · see citing works
mGluRs: a target for pharmacotherapy in Parkinson disease
Kearney, J. A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00391-1 · Cited by 27 · see citing works
Jia, Y., Deng, J., Zhang, W., Sun, Z., Yang, J., Yu, Y., Gong, X., Jia, J., & Wang, X. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12587 · Cited by 26 · see citing works
Therapeutic Potential of Targeting Metabotropic Glutamate Receptors for Parkinson’s Disease
Dickerson, J. W., & Conn, P. J. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.6 · Cited by 26 · see citing works
Self-citationWarnock, G., Sommerauer, M., Mu, L., Gonzalez, G. P., Geistlich, S., Treyer, V., Schibli, R., Buck, A., Krämer, S. D., & Ametamey, S. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3879-x · Cited by 26 · see citing works
Lemos, A., Melo, R., Preto, A. J., de Almeida, J. G., Moreira, I. S., & Cordeiro, M. N. D. S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180308161642 · Cited by 26 · see citing works
Wardas, J., Pietraszek, M., Wolfarth, S., & Ossowska, K. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.002 · Cited by 26 · see citing works
Wittmann, M., Hubert, G. W., Smith, Y., & Conn, P. J. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00254-8 · Cited by 25 · see citing works
Self-citationShen, K., & Johnson, S. W. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.052209 · Cited by 23 · see citing works
Domenici, M. R., Potenza, R. L., Martire, A., Coccurello, R., Pèzzola, A., Reggio, R., Tebano, M. T., & Popoli, P. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20489 · Cited by 22 · see citing works
Sułkowski, G., Dąbrowska‐Bouta, B., & Strużyńska, L. (2013) · BioMed Research International · doi:10.1155/2013/186068 · Cited by 22 · see citing works
Gołembiowska, K., Konieczny, J., Ossowska, K., & Wolfarth, S. (2002) · Amino Acids · doi:10.1007/s00726-001-0129-z · Cited by 22 · see citing works
Bazyan, A. S., & van Luijtelaar, G. (2013) · ISRN Neurology · doi:10.1155/2013/875834 · Cited by 21 · see citing works
Lewis, M. H., Lindenmaier, Z., Boswell, K., Edington, G., King, M. A., & Muehlmann, A. M. (2018) · Genes Brain & Behavior · doi:10.1111/gbb.12468 · Cited by 21 · see citing works
Zheng, C., Xu, Y., Chen, G., Tan, Y., Zeng, W., Wang, J., Cheng, C., Yang, X., Nie, S., Zhang, Z., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104807 · Cited by 21 · see citing works
Campusano, J. M., Abarca, J., Forray, M. I., Gysling, K., & Bustos, G. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00870-5 · Cited by 20 · see citing works
Role of medial hypothalamic orexin system in panic, phobia and hypertension
de Abreu, A. R. R., Molosh, A. I., Johnson, P. L., & Shekhar, A. (2018) · Brain Research · doi:10.1016/j.brainres.2018.09.010 · Cited by 19 · see citing works
Role of metabotropic glutamate receptors in animal models of Parkinson's disease.
Senkowska, A., & Ossowska, K. (2003) · PubMed · Cited by 19 · see citing works
Parnas, H., Valle-Lisboa, J. C., & Segel, L. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242549999 · Cited by 17 · see citing works
Villalba, R. M., Raju, D. V., Hall, R. A., & Smith, Y. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20950 · Cited by 16 · see citing works
Role of metabotropic glutamate receptors in CNS disorders
O’Connor, R. M., & Cryan, J. F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511760334.017 · Cited by 14 · see citing works
Yang, T., Xu, Y., Cheng, C., Zheng, C., Zeng, W., Wang, J., Zhang, X., Yang, X., Wang, J., Yang, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00183 · Cited by 14 · see citing works
- Authors
- Bradley, S. R., Marino, M. J., Wittmann, M., Rouse, S. T., Awad, H., Levey, A. I., & Conn, P. J.
- Affiliations
- University of Tübingen (DE)
- Emory University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2000-05-01
- Volume
- 20
- Issue
- 9
- Pages
- 3085-3094
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6773118
- OpenAlex
- W1926939570
- Cited by
- 141
- References
- 54
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Journal of Neuroscience Nursing
- Funders
- National Parkinson Foundation
- Emory University
- National Institutes of Health
- U.S. Army
- Parkinsonfonden
- Topics
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- group II metabotropic glutamate receptors, substantia nigra pars reticulata, subthalamic nucleus, Parkinson's disease, basal ganglia, glutamatergic synapses, presynaptic inhibition, catalepsy, mGluR agonists, glutamatergic neurons
- MeSH terms
- Animals, Bridged Bicyclo Compounds, Catalepsy, Haloperidol, Male, Parkinson Disease, Substantia Nigra, Rats, Sprague-Dawley, Receptors, Presynaptic, Receptors, Metabotropic Glutamate, Dopamine Antagonists, Excitatory Amino Acid Agonists, Glutamic Acid, Excitatory Postsynaptic Potentials, Subthalamic Nucleus, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review